Valbiotis (XPAR:ALVAL) Loans Receivable: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALVAL Valbiotis SA XPAR:ALVAL
60 GF Score
Price €0.80
GF Value €1.47
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Valbiotis Loans Receivable?

Valbiotis XPAR:ALVAL +1.14% 60 Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVAL with a GF Score™ of 60/100 and a GF Value™ of €1.47 (Possible Value Trap). The stock has 6 warning signs investors should review.

Valbiotis's Loans Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Valbiotis Loans Receivable Historical Data

* Premium members only.

The historical data trend for Valbiotis's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valbiotis Loans Receivable Chart

Valbiotis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Valbiotis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALVAL
60GF Score
Valbiotis SA XPAR:ALVAL
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valbiotis Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
Valbiotis (XPAR:ALVAL) has a Loans Receivable of €0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Valbiotis and its competitors.
Is Valbiotis' Loans Receivable too high?
Valbiotis' current Loans Receivable is €0.00 Mil. Overall, Valbiotis has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' Loans Receivable compare to KHC and GIS?
Valbiotis' Loans Receivable of €0.00 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Consumer Packaged Goods company?
A good Loans Receivable depends on the Consumer Packaged Goods industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Valbiotis and its competitors. Valbiotis's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.80 — trading 45.7% below its estimated fair value. The current Loans Receivable is €0.00 Mil. Valbiotis' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?

Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued. The current stock price of €0.80 is trading 45.7% below its estimated GF Value™ of €1.47. GuruFocus considers Valbiotis to be Possible Value Trap.

Key valuation signals for XPAR:ALVAL:

  • Loans Receivable: €0.00 Mil
  • GF Value™: €1.47 vs. price of €0.80 (45.7% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valbiotis Business Description

Other Exchanges 8JD:Germany
Address 12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
60GF Score

Get the complete analysis for XPAR:ALVAL

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€1.47
GF Value